Clinical value of soluble tumor necrosis factor-alpha receptors in patients with systemic lupus erythematosus

• Published in: Klinicheskaia meditsina Vol. 82; no. 10; p. 51
• Main Authors: Krichevskaia, O A, Kliukvina, N G, Aleksandrova, E N, Samsonov, M Iu, Nasonov, E L
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2004
• Subjects: Adolescent; Adult; Biomarkers; Disease Progression; Female; Humans; Immunoenzyme Techniques; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - diagnosis; Male; Middle Aged; Molecular Weight; Prognosis; Receptors, Tumor Necrosis Factor - blood
• ISSN: 0023-2149

The study was undertaken to examine the clinical value of serum levels of soluble receptors of tumor necrosis factor-alpha with a molecular mass of 55 kDa (rTNF-alpha-55R) in patients with systemic lupus erythematosus (SLE). The serum level of rTNF-alpha-55R was measured by enzyme immunoassay (a "Quantikine" set, R&D System, USA) in 73 patients with SLE and 22 donors. In the patients, the mean level of rTNF-alpha-55R was significantly higher than that in donors. Higher serum levels of rTNF-alpha-55R were noted in 43.8% of the patients with SLE. There was a correlation between the level of rTNF-alpha-55R and the progression of SLE (p < 0.05), the exacerbation (p < 0.05), and the clinical manifestations of the disease (cardiac valvular apparatus damage, active lupus nephritis). rTNF-alpha-55R are a marker of the progression and exacerbation of SLE and reflects that there is a prognostically poor factor, i.e. the involvement of the kidneys in a pathological process.